The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability
Abstract
A biopharmaceutics drug classification scheme for correlating in vitro drug product dissolution and in vivo bioavailability is proposed based on recognizing that drug dissolution and gastrointestinal permeability are the fundamental parameters controlling rate and extent of drug absorption. This analysis uses a transport model and human permeability results for estimating in vivo drug absorption to illustrate the primary importance of solubility and permeability on drug absorption. The fundamental parameters which define oral drug absorption in humans resulting from this analysis are discussed and used as a basis for this classification scheme. These Biopharmaceutic Drug Classes are defined as: Case 1. High solubility-high permeability drugs, Case 2. Low solubility-high permeability drugs, Case 3. High solubility-low permeability drugs, and Case 4. Low solubility-low permeability drugs. Based on this classification scheme, suggestions are made for setting standards for in vitro drug dissolution testing methodology which will correlate with the in vivo process. This methodology must be based on the physiological and physical chemical properties controlling drug absorption. This analysis points out conditions under which no in vitro-in vivo correlation may be expected e.g. rapidly dissolving low permeability drugs. Furthermore, it is suggested for example that for very rapidly dissolving high solubility drugs, e.g. 85% dissolution in less than 15 minutes, a simple one point dis…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Gastroparesis caused by non-pharmacologic etiologies is indeed known to affect drug absorption [6, 7].”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [6]
In the citing paper
“Application of the BCS in waiving BA/BE requirements is based on premises that if (1) two immediate-release (IR) drug formulations/products behave as oral solutions within the GI tract due to high solubility and rapid dissolution, (ii) no precipitation occurs in the GI tract once the API is dissolved, and (iii) the two IR formulations have the same in vivo dissolution profile under all intestinal”
From BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements (2016) · cites this paper as [4]
In the citing paper
“The Biopharmaceutics Classification System (BCS), based on aqueous solubility and intestinal permeability, has enjoyed wide use since 1995 as a mechanism for waiving in vivo bioavailability and bioequivalence studies.”
From BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements (2016) · cites this paper as [4]
Citations
Cites
Diffusion, mass transfer in fluid systems
(1997) · Choice Reviews Online · doi:10.5860/choice.35-0927 · Cited by 4,930
Transit of pharmaceutical dosage forms through the small intestine.
Davis, S. S., Hardy, J. G., & Fara, J. W. (1986) · Gut · doi:10.1136/gut.27.8.886 · Cited by 853
The effect of particle size distribution on dissolution rate and oral absorption
HINTZ, R., & JOHNSON, K. (1989) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(89)90069-0 · Cited by 331
Amidon, G. L., Sinko, P. J., & Fleisher, D. (1988) · Pharmaceutical Research · doi:10.1023/a:1015927004752 · Cited by 300
Self-citationOh, D.-M., Curl, R. L., & Amidon, G. L. (1993) · Pharmaceutical Research · doi:10.1023/a:1018947113238 · Cited by 253
Self-citationRegional Rectal Perfusion: A New in Vivo Approach to Study Rectal Drug Absorption in Man
Lennernäs, H., Fagerholm, U., Raab, Y., Gerdin, B., & Hällgren, R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016216905197 · Cited by 219
Self-citationOberle, R. L., & Amidon, G. L. (1987) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01061761 · Cited by 208
Self-citationRegional Jejunal Perfusion, a New in Vivo Approach to Study Oral Drug Absorption in Man
Lennernäs, H., Ahrenstedt, Ö., Hällgren, R., Knutson, L., Ryde, M., & Paalzow, L. K. (1992) · Pharmaceutical Research · doi:10.1023/a:1015888813741 · Cited by 202
Self-citationPredicting Fraction Dose Absorbed in Humans Using a Macroscopic Mass Balance Approach
Sinko, P. J., Leesman, G. D., & Amidon, G. L. (1991) · Pharmaceutical Research · doi:10.1023/a:1015892621261 · Cited by 178
Self-citationIn Vitro Dissolution Profile of Water-Insoluble Drug Dosage Forms in the Presence of Surfactants
Shah, V. P., Konecny, J. J., Everett, R. L., McCullough, B., Noorizadeh, A. C., & Skelly, J. P. (1989) · Pharmaceutical Research · doi:10.1023/a:1015909716312 · Cited by 162
Self-citation
Research works printed but not linked: 5
- E.M. Topp, Physiological Flow Models for Intestinal Absorption and Plasma Kinetics of Aspirin, Thesis, The University of Michigan (1986).
- G.D. Leesman, P.J. Sinko, and G.L. Amidon, Simulation of Oral Drug Absorption: Gastric Emptying and Gastrointestinal Motility, in: Pharmacokinetics, P.W. Welling and F.L.S. Tse, Editors, Marcel Dekker, Inc., (NY) 1988, Ch 6, p 267.
- V.G. Levich, Physico-Chemical Hydrodynamics, Prentice-Hall, Englewood Cliffs, NJ (1962).
- H.M. Abdou, Dissolution, Bioavailability, & Bioequivalence, A. Gennaro, B. Migdalof, G.L. Hassert and T. Medwick (Eds), Mack Publishing Co., Easton PA (1989).
- The Merck Index, Tenth Edition, Merck & Co., Inc., Rahway, NJ (1983).
Cited by
Items 201–300 of 1,018
Daughton, C. G., & Ruhoy, I. S. (2009) · Environmental Toxicology and Chemistry · doi:10.1897/08-382.1 · Cited by 234
“[70], is a system for classifying APIs according to bioavailability.”
BackgroundUse of the Biopharmaceutical Classification System in Early Drug Development
Ku, M. S. (2008) · The AAPS Journal · doi:10.1208/s12248-008-9020-0 · Cited by 229
Vithani, K., Goyanes, A., Jannin, V., Basit, A. W., Gaisford, S., & Boyd, B. J. (2019) · Pharmaceutical Research · doi:10.1007/s11095-018-2531-1 · Cited by 233
Overview of nanoparticulate strategies for solubility enhancement of poorly soluble drugs
Khan, K. U., Minhas, M. U., Badshah, S. F., Suhail, M., Ahmad, A., & Ijaz, S. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120301 · Cited by 220
Estimating drug solubility in the gastrointestinal tract
Dressman, J. B., Vertzoni, M., Goumas, K., & Reppas, C. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.009 · Cited by 237
Agrawal, M., Saraf, S., Saraf, S., Dubey, S. K., Puri, A., Patel, R. J., Ajazuddin, Ravichandiran, V., Murty, U. S., & Alexander, A. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.02.020 · Cited by 230
Nanotechnology as Emerging Tool for Enhancing Solubility of Poorly Water-Soluble Drugs
Kumar, S., Dilbaghi, N., Saharan, R., & Bhanjana, G. (2012) · BioNanoScience · doi:10.1007/s12668-012-0060-7 · Cited by 227
“The Biopharmaceutical Classification System (BCS) is a scientific framework for classifying a drug substance based on its aqueous solubility and intestinal permeability [4, 5].”
BackgroundLaxmi, M., Bhardwaj, A., Mehta, S., & Mehta, A. (2015) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.3109/21691401.2014.887018 · Cited by 225
“Lipid based drug delivery systems provide an advanced approach to enhance drug solubilization in the GIT thus to improve the oral bioavailability of poorly soluble drugs (Baboota et al. 2007, Amidon et al. 1995).”
BackgroundCocrystals to facilitate delivery of poorly soluble compounds beyond-rule-of-5
Kuminek, G., Cao, F., Bahia de Oliveira da Rocha, A., Gonçalves Cardoso, S., & Rodríguez-Hornedo, N. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.022 · Cited by 230
“Dissolution rate is one of the important factors that governs the bioavailability of oral drugs, especially for those with dissolution rate limited absorption [95].”
Lakshman, J. P., Cao, Y., Kowalski, J., & Serajuddin, A. T. M. (2008) · Molecular Pharmaceutics · doi:10.1021/mp8001073 · Cited by 236
Dahan, A., & Hoffman, A. (2007) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2007.01.017 · Cited by 230
A Review of Food–Drug Interactions on Oral Drug Absorption
Deng, J., Zhu, X., Chen, Z., Fan, C. H., Kwan, H. S., Wong, C. H., Shek, K. Y., Zuo, Z., & Lam, T. N. (2017) · Drugs · doi:10.1007/s40265-017-0832-z · Cited by 226
“Unlike the previous Biopharmaceutics Classification System (BCS) [189], the BDDCS replaces the permeability criteria with the metabolism extent.”
InfluentialRole of Nanotechnology in Pharmaceutical Product Development
Devalapally, H., Chakilam, A., & Amiji, M. M. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20875 · Cited by 230
Parasrampuria, D. A., & Truitt, K. E. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0342-7 · Cited by 229
“In addition, its permeability in Caco-2 cells is poor [18], making it a Biopharmaceutics Classification System class IV compound [19].”
BackgroundSafety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic
Maher, S., Leonard, T. W., Jacobsen, J., & Brayden, D. J. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.09.006 · Cited by 227
“The biopharmaceutics classification system (BSC) categorizes soluble drugs with poor intestinal permeability as Class III drugs [6].”
Ong, S., Ming, L., Lee, K., & Yuen, K. (2016) · Pharmaceutics · doi:10.3390/pharmaceutics8030025 · Cited by 221
Avdeef, A. (2005) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.1.2.325 · Cited by 222
“This is exemplified in several well-known schemes, such as the absorption potential [1,2], the biopharmaceutics classification system [3-6] and the maximum absorbable dose (MAD) model [7,8].”
BackgroundStrategies for Absorption Screening in Drug Discovery and Development
Bohets, H., Annaert, P., Mannens, G., van Beijsterveldt, L., Anciaux, K., Verboven, P., Meuldermans, W., & Lavrijsen, K. (2001) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026013394886 · Cited by 230
Yu, L., Bridgers, A., Polli, J., Vickers, A., Long, S., Roy, A., Winnike, R., & Coffin, M. (1999) · Pharmaceutical Research · doi:10.1023/a:1018939006780 · Cited by 225
Comparison of Electrospun and Extruded Soluplus®-Based Solid Dosage Forms of Improved Dissolution
Nagy, Z. K., Balogh, A., Vajna, B., Farkas, A., Patyi, G., Kramarics, Á., & Marosi, G. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22731 · Cited by 221
Review and analysis of FDA approved drugs using lipid-based formulations
Savla, R., Browne, J., Plassat, V., Wasan, K. M., & Wasan, E. K. (2017) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2017.1342654 · Cited by 225
“The BCS was proposed by Amidon and colleagues to correlate in vitro dissolution and in vivo bioavailability and illustrate that solubility and permeability were important to oral drug absorption [37].”
MethodDahan, A., Miller, J. M., Hoffman, A., Amidon, G. E., & Amidon, G. L. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22033 · Cited by 224
Self-citationHuman Jejunal Effective Permeability and Its Correlation with Preclinical Drug Absorption Models
LennernÄs, H. (1997) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1997.tb06084.x · Cited by 223
Self-citationBioavailability and Bioequivalence: An FDA Regulatory Overview
Chen, M.-L., Shah, V., Patnaik, R., Adams, W., Hussain, A., Conner, D., Mehta, M., Malinowski, H., Lazor, J., Huang, S.-M., et al. (2001) · Pharmaceutical Research · doi:10.1023/a:1013319408893 · Cited by 221
“More recently, a biopharmaceutics classification system (BCS) categorizes drug substances as having either high or low solubility and permeability and drug products as exhibiting rapid dissolution (22).”
BackgroundSelf-citationA new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption
Hong, J.-Y., Kim, J.-K., Song, Y.-K., Park, J.-S., & Kim, C.-K. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.10.002 · Cited by 220
Phillips, D. J., Pygall, S. R., Cooper, V. B., & Mann, J. C. (2012) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2012.01523.x · Cited by 213
“In 1995 Amidon et al. proposed the classification of drugs on the basis of aqueous solubility and intestinal permeability.”
MethodInfluentialBiopharmaceutical classification of poorly soluble drugs with respect to “enabling formulations”
Buckley, S. T., Frank, K. J., Fricker, G., & Brandl, M. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.04.002 · Cited by 213
“Drug bioavailability prediction relies on the principles originally laid down in the Biopharmaceutical Classification Scheme (BCS, Amidon et al., 1995).”
Xu, R., Wang, K., Rizzi, J. P., Huang, H., Grina, J. A., Schlachter, S. T., Wang, B., Wehn, P. M., Yang, H., Dixon, D. D., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00719 · Cited by 220
Lennernäs, H., & Abrahamsson, B. (2005) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357055263 · Cited by 215
“…(BCS) has been developed to provide a scientific approach for classifying drug compounds based on solubility as related to dose and intestinal permeability in combination with the dissolution properties of the oral immediate-release dosage form (Amidon et al 1995; CDER/FDA 2000; Yu et al 2002).”
BackgroundInfluentialSelf-citationDalvi, S. V., & Dave, R. N. (2009) · Industrial & Engineering Chemistry Research · doi:10.1021/ie900248f · Cited by 216
Narang, J., Khan, S., Baboota, S., Ali, J., Khan, S., & Narang, R. (2015) · International Journal of Pharmaceutical Investigation · doi:10.4103/2230-973x.167661 · Cited by 202
“Usually, such drugs are codified as Class II or IV as per biopharmaceutical classification system (BCS), [6] and they exhibit low oral bioavailability, which is attributed to their poor water solubility.”
Zaki, N. M., Awad, G. A., Mortada, N. D., & Abd ElHady, S. S. (2007) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2007.08.006 · Cited by 214
Naylor, M. R., Ly, A. M., Handford, M. J., Ramos, D. P., Pye, C. R., Furukawa, A., Klein, V. G., Noland, R. P., Edmondson, Q., Turmon, A. C., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01259 · Cited by 205
Solubility and Dissolution Profile Assessment in Drug Discovery
Sugano, K., Okazaki, A., Sugimoto, S., Tavornvipas, S., Omura, A., & Mano, T. (2007) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.22.225 · Cited by 212
High speed electrospinning for scaled-up production of amorphous solid dispersion of itraconazole
Nagy, Z. K., Balogh, A., Démuth, B., Pataki, H., Vigh, T., Szabó, B., Molnár, K., Schmidt, B. T., Horák, P., Marosi, G., et al. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.01.025 · Cited by 213
“All rights reserved. but high permeability) according to the Biopharmaceutical Classification System (BCS) (Amidon et al., 1995).”
BackgroundFast disintegrating tablets: Opportunity in drug delivery system
Parkash, V., Maan, S., Deepika, Yadav, S., Hemlata, & Jogpal, V. (2011) · Journal of Advanced Pharmaceutical Technology & Research · doi:10.4103/2231-4040.90877 · Cited by 210
Pharmacokinetics in Drug Discovery
Ruiz-Garcia, A., Bermejo, M., Moss, A., & Casabo, V. G. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21009 · Cited by 199
Alginate Particles as Platform for Drug Delivery by the Oral Route: State-of-the-Art
Sosnik, A. (2014) · ISRN Pharmaceutics · doi:10.1155/2014/926157 · Cited by 206
“The most common (bio)pharmaceutic drawback that pharmaceutical scientists face is poor aqueous solubility [4–7], followed by limited drug permeability [4, 7] and physicochemical instability [8].”
BackgroundLiu, D., Mao, Y., Ding, L., & Zeng, X.-A. (2019) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2019.07.038 · Cited by 212
“Biopharmaceutics classification system (BCS) is a useful tool for decision-making in formulation development (Amidon, Lennernas, Shah, & Crison, 1995) .”
MethodIntestinal efflux transporters and drug absorption
Murakami, T., & Takano, M. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.7.923 · Cited by 201
“Amidon’s group proposed a Biopharmaceutics Classification System (BCS) that categorized drugs into four classes according to their solubility and permeability, from the viewpoint that the fundamental parameters controlling the rate and extent of oral drug absorption are the drug’s aqueous solubility and gastrointestin…”
BackgroundMethodNicolaides, E., Symillides, M., Dressman, J. B., & Reppas, C. (2001) · Pharmaceutical Research · doi:10.1023/a:1011071401306 · Cited by 208
“The absorption process of a lipophilic drug is often assumed to be determined mainly by its intralumenal dissolution process (1,2).”
BackgroundSugano, K., Hamada, H., Machida, M., & Ushio, H. (2001) · SLAS Discovery · doi:10.1177/108705710100600309 · Cited by 202
Raw, A. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.10.011 · Cited by 206
Perucca, E., & Bialer, M. (2020) · CNS Drugs · doi:10.1007/s40263-020-00741-5 · Cited by 193
Shah, N., Iyer, R. M., Mair, H.-J., Choi, D., Tian, H., Diodone, R., Fahnrich, K., Pabst-Ravot, A., Tang, K., Scheubel, E., et al. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23425 · Cited by 202
Biopharmaceutics classification and intestinal absorption study of apigenin
Zhang, J., Liu, D., Huang, Y., Gao, Y., & Qian, S. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.07.002 · Cited by 201
Dahan, A., Beig, A., Lindley, D., & Miller, J. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.018 · Cited by 200
“[4] developed the biopharmaceutics classification system (BCS), that pinpoints the drug solubility/dissolution in the aqueous gastrointestinal (GI) milieu, and the permeability”
BackgroundGastrointestinal Transit and Drug Absorption
Kimura, T., & Higaki, K. (2002) · Biological & Pharmaceutical Bulletin · doi:10.1248/bpb.25.149 · Cited by 205
Feasibility studies of utilizing disk intrinsic dissolution rate to classify drugs
Yu, L. X., Carlin, A. S., Amidon, G. L., & Hussain, A. S. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2003.10.016 · Cited by 208
Self-citationEffect of Common Excipients on Caco-2 Transport of Low-Permeability Drugs
Rege, B. D., Yu, L. X., Hussain, A. S., & Polli, J. E. (2001) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.1127 · Cited by 206
Constantinides, P. P., & Wasan, K. M. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20780 · Cited by 207
Nanoparticulate Delivery Systems for Antiviral Drugs
Lembo, D., & Cavalli, R. (2010) · Antiviral Chemistry and Chemotherapy · doi:10.3851/imp1684 · Cited by 203
“[3] classified all the orally administered drugs into four classes (I, II, III and IV) according to decreasing solubility and permeability values using the Biopharmaceutics Classification System (BCS).”
MethodMiller, J. M., Beig, A., Krieg, B. J., Carr, R. A., Borchardt, T. B., Amidon, G. E., Amidon, G. L., & Dahan, A. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200181v · Cited by 204
Self-citationBitter, C., Suter-Zimmermann, K., & Surber, C. (2011) · Current Problems in Dermatology · doi:10.1159/000321044 · Cited by 198
Strategies for formulating and delivering poorly water-soluble drugs
Rodriguez-Aller, M., Guillarme, D., Veuthey, J.-L., & Gurny, R. (2015) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2015.05.009 · Cited by 196
Bikiaris, D. N. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.618181 · Cited by 198
“According to the Biopharmaceutics Classification System (BCS), drug compounds are divided into four classes taking into account the drug aqueous solubility and drug intestinal permeability, in order to outline the importance of the aqueous solubility and dissolution behavior of drugs for their bioavailability, that is…”
MethodOvercoming poor oral bioavailability using nanoparticle formulations – opportunities and limitations
Desai, P. P., Date, A. A., & Patravale, V. B. (2012) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2011.12.001 · Cited by 199
Dahan, A., & Hoffman, A. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9054-x · Cited by 195
Computational prediction of formulation strategies for beyond-rule-of-5 compounds
Bergström, C. A. S., Charman, W. N., & Porter, C. J. H. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.02.005 · Cited by 187
“The larger the circle the larger the fraction of upper right (green) corner, BCS class 2-like compounds in the lower right (yellow) corner, upper left panel shows the distribution of all 1620 ligands without identifying the target re almost entirely BCS Class 2 and macrolides are largely BCS class 3. aripiprazole and…”
MethodInfluentialAbuzar, S. M., Hyun, S.-M., Kim, J.-H., Park, H. J., Kim, M.-S., Park, J.-S., & Hwang, S.-J. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.12.041 · Cited by 191
“…solubility and high permeability), class III (high solubility and low permeability), and class IV (low solubility and low permeability) (Figure 1A), to AC CE PT ED M AN US CR IP T correlate in vitro drug dissolution with in vivo bioavailability (Amidon et al., 1995; Lobenberg and Amidon, 2000).”
A dynamic in vitro lipolysis model
Zangenberg, N. H., Müllertz, A., Gjelstrup Kristensen, H., & Hovgaard, L. (2001) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(01)00182-8 · Cited by 194
Pharmaceutical cocrystals, salts and polymorphs: Advanced characterization techniques
Pindelska, E., Sokal, A., & Kolodziejski, W. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.09.014 · Cited by 193
Dissolution Rate and Apparent Solubility of Poorly Soluble Drugs in Biorelevant Dissolution Media
Fagerberg, J. H., Tsinman, O., Sun, N., Tsinman, K., Avdeef, A., & Bergström, C. A. S. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100049m · Cited by 187
Skin–PAMPA: A new method for fast prediction of skin penetration
Sinkó, B., Garrigues, T. M., Balogh, G. T., Nagy, Z. K., Tsinman, O., Avdeef, A., & Takács-Novák, K. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.01.011 · Cited by 186
An Integrated Model for Determining Causes of Poor Oral Drug Absorption
Yu, L. X. (1999) · Pharmaceutical Research · doi:10.1023/a:1018911728161 · Cited by 185
Fahr, A., Hoogevest, P. V., May, S., Bergstrand, N., & S. Leigh, M. L. (2005) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.05.012 · Cited by 189
Christensen, J. Ø., Schultz, K., Mollgaard, B., Kristensen, H. G., & Mullertz, A. (2004) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2004.08.003 · Cited by 186
Rahman, M. A., Hussain, A., Hussain, M. S., Mirza, M. A., & Iqbal, Z. (2013) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2012.660949 · Cited by 183
Zhang, J., Hu, K., Di, L., Wang, P., Liu, Z., Zhang, J., Yue, P., Song, W., Zhang, J., Chen, T., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113964 · Cited by 175
Van Eerdenbrugh, B., Baird, J. A., & Taylor, L. S. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22214 · Cited by 182
Lembo, D., Swaminathan, S., Donalisio, M., Civra, A., Pastero, L., Aquilano, D., Vavia, P., Trotta, F., & Cavalli, R. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.12.031 · Cited by 184
“It is 297 reported in the BCS classification developed by Gordon Amidon (Amidon et al., 1995) as a class 298 III drug; i.e. soluble with low intestinal permeability.”
BackgroundSelf-nano-emulsifying drug delivery systems: an update of the biopharmaceutical aspects
Cherniakov, I., Domb, A. J., & Hoffman, A. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.999038 · Cited by 180
“It is worth noting that for BCS Class II compounds, which are commonly formulated into SNEDDS, poor permeability is not a limiting factor in their absorption pathway [3].”
BackgroundCharalabidis, A., Sfouni, M., Bergström, C., & Macheras, P. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.05.041 · Cited by 170
Vogelpoel, H., Welink, J., Amidon, G. L., Junginger, H. E., Midha, K. K., Möller, H., Olling, M., Shah, V. P., & Barends, D. M. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20131 · Cited by 179
“developed by Amidon et al.(1) and is known as the Biopharmaceutics Classification System (BCS).”
BackgroundInfluentialSelf-citationFlow and Thixotropic Parameters for Rheological Characterization of Hydrogels
Ghica, M., Hîrjău, M., Lupuleasa, D., & Dinu-Pîrvu, C.-E. (2016) · Molecules · doi:10.3390/molecules21060786 · Cited by 177
Application of hydrogen bonding calculations in property based drug design
Abraham, M. H., Ibrahim, A., Zissimos, A. M., Zhao, Y. H., Comer, J., & Reynolds, D. P. (2002) · Drug Discovery Today · doi:10.1016/s1359-6446(02)02478-9 · Cited by 180
Link between drug absorption solubility and permeability measurements in Caco-2 cells
Pade, V., & Stavchansky, S. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js980111k · Cited by 186
Solubility and dissolution enhancement strategies: current understanding and recent trends
Jain, S., Patel, N., & Lin, S. (2015) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2014.971027 · Cited by 169
Biowaiver monographs for immediate release solid oral dosage forms: Acetaminophen (paracetamol)
Kalantzi, L., Reppas, C., Dressman, J. B., Amidon, G. L., Junginger, H. E., Midha, K. K., Shah, V. P., Stavchansky, S. A., & Barends, D. M. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20477 · Cited by 182
Self-citationB. Shekhawat, P., & B. Pokharkar, V. (2017) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.09.005 · Cited by 176
Nanocrystals as a master key to deliver hydrophobic drugs via multiple administration routes
McGuckin, M. B., Wang, J., Ghanma, R., Qin, N., Palma, S. D., Donnelly, R. F., & Paredes, A. J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.012 · Cited by 168
Ku, M. S., & Dulin, W. (2012) · Pharmaceutical Development and Technology · doi:10.3109/10837450.2010.535826 · Cited by 172
“Solubility criteria The Biopharmaceutics Classification System (BCS)([18]) is not only a useful tool for obtaining waivers for in-vivo bioequivalence studies but also for decision making in the discovery and early development of new drugs as suggested by FDA.”
MethodEhrhardt, C., & Kim, K. (2007) · Springer eBooks · doi:10.1007/978-0-387-74901-3 · Cited by 183
Quantitative Biopharmaceutics Classification System: The Central Role of Dose/Solubility Ratio
Rinaki, E., Valsami, G., & Macheras, P. (2003) · Pharmaceutical Research · doi:10.1023/b:pham.0000008037.57884.11 · Cited by 176
“the choice of Papp in the QBCS: (a) it is currently used as the most widespread predictor of drug absorption (15,23); (b) it is relatively easily measured experimentally; and (c) correlations have been developed (15,24) between Papp and the wall permeability coefficient Peff, which is directly related to MAT (1).”
BackgroundMethodResultInfluentialPharmaceutical excipients — quality, regulatory and biopharmaceutical considerations
Elder, D. P., Kuentz, M., & Holm, R. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.12.018 · Cited by 169
Chiappetta, D. A., Hocht, C., Taira, C., & Sosnik, A. (2010) · Nanomedicine · doi:10.2217/nnm.09.90 · Cited by 174
Silica-based systems for oral delivery of drugs, macromolecules and cells
Diab, R., Canilho, N., Pavel, I. A., Haffner, F. B., Girardon, M., & Pasc, A. (2017) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2017.04.005 · Cited by 173
de Waard, H., Hinrichs, W. L. J., & Frijlink, H. W. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.03.002 · Cited by 175
DiNunzio, J. C., Miller, D. A., Yang, W., McGinity, J. W., & Williams, R. O. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800042d · Cited by 175
Neuroprotective Potential of Ellagic Acid: A Critical Review
Gupta, A., Singh, A. K., Kumar, R., Jamieson, S., Pandey, A. K., & Bishayee, A. (2021) · Advances in Nutrition · doi:10.1093/advances/nmab007 · Cited by 168
Kuś-Słowińska, M., Ibragimow, I., & Piotrowska‐Kempisty, H. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15112523 · Cited by 179
“The Biopharmaceutics Classifi-cation System (BCS), as defined by Amidon et al., is a widely used tool for predicting the in vivo BA of a drug substance in in vitro conditions [9].”
MethodJohannsson, G., Bergthorsdottir, R., Nilsson, A. G., Lennernas, H., Hedner, T., & Skrtic, S. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0170 · Cited by 173
Self-citationBioavailability of indomethacin-saccharin cocrystals
Jung, M.-S., Kim, J.-S., Kim, M.-S., Alhalaweh, A., Cho, W., Hwang, S.-J., & Velaga, S. P. (2010) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2010.01189.x · Cited by 171
“In particular, Biopharmaceutical Classification System (BCS) class II drugs, which permeate membranes well but are poorly soluble, often show dissolution-limited bioavailability.([1]) The solubility and dissolution rate primarily depend on the solid-state form of the active pharmaceutical ingredients (APIs).”
BackgroundHan, X., Ghoroi, C., To, D., Chen, Y., & Davé, R. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.05.070 · Cited by 170
Biopharmaceutics and pharmacokinetics in drug research
Panchagnula, R. (2000) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(00)00344-6 · Cited by 168
Liu, C., Chen, Z., Chen, Y., Lu, J., Li, Y., Wang, S., Wu, G., & Qian, F. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00837 · Cited by 168
Talegaonkar, S., & Bhattacharyya, A. (2019) · AAPS PharmSciTech · doi:10.1208/s12249-019-1337-8 · Cited by 165
“(1), for any drug, its solubility in the gastrointestinal fluid and permeability across the biological membrane are the key parameters affecting oral bioavailabil-”
BackgroundClinical study of solid dispersions of itraconazole prepared by hot-stage extrusion
Six, K., Daems, T., de Hoon, J., Van Hecken, A., Depre, M., Bouche, M.-P., Prinsen, P., Verreck, G., Peeters, J., Brewster, M. E., et al. (2005) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2004.10.005 · Cited by 170
Recent strategies in spray drying for the enhanced bioavailability of poorly water-soluble drugs
Davis, M., & Walker, G. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.005 · Cited by 163
Lennernäs, H., Nylander, S., & Ungell, A.-L. (1997) · Pharmaceutical Research · doi:10.1023/a:1012121632357 · Cited by 173
Self-citation
Metadata
- Authors
- Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R.
- Affiliations
- University of Michigan (US)
- Uppsala University (SE)
- United States Food and Drug Administration (US)
- Therapeutics Systems Research Laboratories (United States) (US)
- Venue
- Pharmaceutical Research
- Published
- 1995-03
- Volume
- 12
- Issue
- 3
- Pages
- 413-420
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W1498305210
- Cited by
- 5,430
- References
- 29
- Citations by year
- 2026: 170 · 2025: 201 · 2024: 182 · 2023: 240 · 2022: 266 · 2021: 282 · 2020: 299 · 2019: 241 · 2018: 278 · 2017: 267 · 2016: 283 · 2015: 283 · 2014: 302 · 2013: 296 · 2012: 302
- FWCI
- 26.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Pharmaceutical Research (publishedVersion)
- PubMed (publishedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- Funders
- U.S. Food and Drug Administration (FD-01462)
- National Institute of General Medical Sciences (GM 37188, R01GM037188)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- in vitro-in vivo correlation, drug dissolution, bioavailability, gastrointestinal permeability, oral drug absorption, solubility, transport modeling, dissolution profile, surfactants
- MeSH terms
- Biological Availability, Cimetidine, Pharmaceutical Preparations, Gastric Emptying, Jejunum, Mathematics, Models, Theoretical, Permeability, Piroxicam, Solubility, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.